Advertisement
Advertisement
U.S. Markets open in 3 hrs 16 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.4000-0.0100 (-0.41%)
At close: 3:30PM EDT
Advertisement
Sign in to post a message.
  • B
    Brad
    Anyone here?
  • M
    Mark
    Hello. Just discovered this company. I didn't understand all fancy terms and technologies the company offers. But numbers seem very disappointing, not backing up its claims in technologies. Quarter ending in 3/31/2021, revenue $559,874, total operating costs/expenses 1,015,430, interest expense -$4,668,064, thus ending net loss of $7,038,686. A restaurant could generate more revenue than that. How can this company sustain? Despite all these poor performance, does this company possess potential to become a solid profit-generating growth business? Do they have a solid plan to fundamentally transform this company to be a money-making business engine? Would love to hear from long-term shareholders here. Thanks.
  • C
    Capitalism
    This company needs a Business Development leader who can deliver a deal or two! Technology alone means nothing unless you have the ability to partner and create value! The CEO does not know how to do so!
    Neutral
  • S
    Scott
    Pressure BioSciences Stock Gains Momentum: Should You Get In? https://twitter.com/PennyStocksN/status/1290997491249356800
  • t
    tom
    Good stock to have in any portfolio now ...got to own this as the technology is completely big in future
    Bullish
  • L
    Leland
    I thought you would like to know the status of the proposed Canaworx merger:

    "The October 31, 2020 deadline (reached after the extension in the Second Amended LOI) in the Binding Agreement and Exclusive Dealing provisions of the Binding LOI is hereby extended to December 31, 2020 (the “Third Amended LOI”). However, this Third Amendment shall expire if CWX doesn’t receive $335,000 for certain obligations to its Immunazin asset, by November 16, 2020. The closing of the Transaction shall be subject to the agreement by both parties of the financial condition of both parties."

    Will PBIO front the money? Who knows?
  • L
    Leland
    As a long suffering investor, looks like PBIO has made the decision to "come out of the closet" and actually apply their technology to real world goods that can be sold in the marketplace. In other words, no longer just an equipment manufacturer. Let's face it folks, sales have been disappointing, and no one else is picking up the gauntlet to actually employ the technology, so good for you, PBIO, let's see what you can do, but mostly can you demonstrate the benefit of the technology, and can you make money?
  • C
    Carl Decicco
    The great technologies are not enough. So the good news is that filing on the extension is October 31 on the potential merger. Should see something hopefully this week or next week since Saturday is the 31st.
    Bullish
  • M
    Mad_Ratter
    The company makes a good product but the sales ramp is too slow. I trimmed big on this run up. ...but the press release today (nothing really new - but it is good PR) combined with the recent favorable price activity could create another short term run. Until last nights PR I thought this would be a sell the news - but the CBD tie in could draw new investors and give us a run to like $9 this week. I'm going to try and get more at the open and play this. I do expect to see $2 again before they really start selling units - but I think we see some craziness this week. GLTA.
  • M
    Mad_Ratter
    Anyone have an update regarding the mergers into Availa Bio? ...this is taking longer to close than initially forecasted.
  • M
    Michael
    This has an extremely low market cap compared to potential!
  • W
    William
    ⭐ This is a very Bullish Chart, traders! 💰💵📈

    https://stockreport.tips/Bullish-Charts
    Bullish
  • t
    tom
    Who buying more today 😊👍
    Bullish
  • G
    Getmoney
    This ones a winner for sure. After reading everything they got coming. This should explode lowest cbd float I know of. 1.75 million shares 😂 To the moon
  • B
    Bill
    Management if your reading now is the time to be knocking on doors for you shear technology for CBD oil!

    Interest in pot-infused drinks is soaring now that cannabis is legal in Canada and hemp-derived CBD is legal in the U.S. Canadian pot company Canopy Growth Corp. is spending up to $150 million on a facility in New York to extract CBD from hemp.

    Constellation Brands Inc., maker of Corona beer, has invested $3.8 billion in Canopy Growth, while Molson Coors Brewing Co. has started a joint venture with Quebec-based Hexo Corp. to sell nonalcoholic cannabis drinks. Even Coca-Cola Co. has said it’s interested in CBD-infused beverages, although it doesn’t have immediate plans to enter the market.

    Plant-based CBD also can be found in personal-care products including moisturizing creams to deodorants and soaps, mostly made by small manufacturers.
  • B
    Bill
    January 24, 2019
    Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018
    https://ir.pressurebiosciences.com/press-releases/detail/297/record-number-of-scientific-papers-citing-the-significant
    Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018
    ir.pressurebiosciences.com
  • B
    Bill
    After Developing A Revolutionary New Nanoemulsion Technology For CBD Oil, Pressure Biosciences Is Worth Watching

    https://seekingalpha.com/article/4247839-developing-revolutionary-new-nanoemulsion-technology-cbd-oil-pressure-biosciences-worth
    Over the past several months, Pressure Biosciences has developed a proprietary shearing technology, which uses high pressure to create nanoemulsions of water an
    Over the past several months, Pressure Biosciences has developed a proprietary shearing technology, which uses high pressure to create nanoemulsions of water an
    seekingalpha.com
  • a
    a p
    Are they invoking the 3 day to disclose rule?
    Management-- Whats going on with the merger??
    G
  • B
    Bill
    looks as though they have some cash now to push forward and get this tech. out to major MJ companies.
    13. Offering and Sales Amounts
    Total Offering Amount $ USD x Indefinite
    Total Amount Sold $ 17459551 USD
    Total Remaining to be Sold $ USD x Indefinite

    Clarification of Response (if Necessary)
    From May 2, 2018 through March 6, 2019, the Company sold the securities detailed in Item 9 for a total purchase price of $4,288,000. During the same period, the company converted debt equal to $13,171,551 into the securities detailed in Item 9.

    14. Investors
    o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering

    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 43

    15. Sales Commissions & Finders' Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions $ 416300 USD o Estimate
    Finders' Fees $ 0 USD o Estimate

    Clarification of Response (if Necessary)
    Warrants for 318,680 shares with an exercise price of $3.50 per share were issued to Garden State as compensation in addition to their sales commissions.

    Filing link:
    https://ir.pressurebiosciences.com/sec-filings?page=1#
    All Filings
    ir.pressurebiosciences.com
  • J
    Jay
    Looks to me like a classic pump and dumper: no earnings, no profits and a stock that has worked its way down from 350 to 3 over the years. Only 17 employees left to rip off the stockholders by collecting paychecks from the financial corpus.
Advertisement
Advertisement